Oncozenge AB (ONCOZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oncozenge AB (ONCOZ) has a cash flow conversion efficiency ratio of 12.336x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.24 Million ≈ $-779.25K USD) by net assets (Skr-587.00K ≈ $-63.17K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Oncozenge AB fund operations to measure how many days the company can operate on defensive assets alone.
Oncozenge AB - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Oncozenge AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Oncozenge AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncozenge AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Global Oriental Bhd
KLSE:1147
|
-0.033x |
|
Educational Development Corporation
NASDAQ:EDUC
|
0.055x |
|
Profithol S.A.
MC:SPH
|
-0.745x |
|
Trustpilot Group PLC
LSE:TRST
|
-5.609x |
|
Commcenter S.A.
MC:CMM
|
0.286x |
|
Peraso Inc
NASDAQ:PRSO
|
-0.229x |
|
General Environmental Conservation Public Company Limited
BK:GENCO
|
0.067x |
|
Wescan Goldfields Inc
V:WGF
|
1.871x |
Annual Cash Flow Conversion Efficiency for Oncozenge AB (2020–2025)
The table below shows the annual cash flow conversion efficiency of Oncozenge AB from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see ONCOZ market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr-587.00K ≈ $-63.17K |
Skr-13.06 Million ≈ $-1.41 Million |
22.244x | +2625.38% |
| 2024-12-31 | Skr9.95 Million ≈ $1.07 Million |
Skr-8.76 Million ≈ $-943.15K |
-0.881x | +3.89% |
| 2023-12-31 | Skr18.64 Million ≈ $2.01 Million |
Skr-17.08 Million ≈ $-1.84 Million |
-0.916x | -41.02% |
| 2022-12-31 | Skr33.97 Million ≈ $3.66 Million |
Skr-22.08 Million ≈ $-2.38 Million |
-0.650x | -995.02% |
| 2021-12-31 | Skr80.32 Million ≈ $8.64 Million |
Skr-4.77 Million ≈ $-513.01K |
-0.059x | -173676.54% |
| 2020-12-31 | Skr29.28 Million ≈ $3.15 Million |
Skr-1.00K ≈ $-107.62 |
0.000x | -- |
About Oncozenge AB
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.